No Data
Castle Biosciences Says Data Shows Efficacy of Its Skin Cancer Tests
Castle Biosciences Presents New Data at ASDS From Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx-Melanoma to Guide SLNB Decisions in T1a Tumors With High-Risk Features and T1b Tumors
Lake Street Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $34
Castle Biosciences Announced The Publication Of Two Recent Studies That Provide Further Support For The Clinical Need Of Its MyPath Melanoma Gene Expression Profile Test Designed To Aid In Providing An Accurate Diagnosis For Ambiguous Melanocytic Lesions
Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential
Castle Biosciences (NASDAQ:CSTL) Spikes 16% This Week, Taking One-year Gains to 157%